Zydus buys rights from Pharmacosmos to sell drug to treat anemia in India, Nepal
MonoFerric injection is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used. MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 9, 2022 Category: Pharmaceuticals Source Type: news

Why Not Everyone Should Take Paxlovid
It’s getting harder to avoid COVID-19, thanks to the dominance of BA.5 in the U.S. and the growing number of other Omicron subvariants. Fortunately, Pfizer’s antiviral treatment Paxlovid can minimize illness from the disease. But it’s not meant for everyone. Only those who are at increased risk for severe disease from COVID-19 qualify for the drug, including people over age 12 who have weakened immune systems or other health conditions that increase risk of serious effects of COVID-19—like asthma, cancer, liver disease, lung disease, heart disease, and obesity. Paxlovid also comes with a list of pot...
Source: TIME: Health - July 22, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Cincinnati startup key player in $330M Blackstone-backed drug collaboration
"This is something that has the potential to replace most IV therapy — and that, to me, is one of the biggest disruptions that I've ever seen in health care.” (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 10, 2022 Category: American Health Authors: Liz Engel Source Type: news

Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program
Australian study (n=107) found a median duration of IV therapy of 3 days, with timely IV-oral switch occurring in 57% of patients. Authors state excessive IV antimicrobial duration was uncommon, but total duration of antibiotic therapy was identified as a target (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 29, 2021 Category: Consumer Health News Source Type: news

Bayers-new-symptomatic-chronic-heart-failure-treatment-Verquvo-vericiguat-approved-in-EU
Approved for adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy / Studied in a population with a high risk of cardiovascular death or heart failure hospitalization / The sGC-stimulator Verquvo provides a specific approach to managing chronic heart failure following a decompensation event (Source: Bayer Company News)
Source: Bayer Company News - July 21, 2021 Category: Pharmaceuticals Source Type: news

One of Dayton's largest physician groups to build new care facility
The health center will feature sixteen exam rooms, spacious waiting areas and a dedicated lab space, as well as procedure, consultation and IV therapy rooms. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 2, 2021 Category: American Health Authors: Jacob Fisher Source Type: news

Positive-CHMP-opinion-for-Bayers-new-symptomatic-chronic-heart-failure-treatment-vericiguat
Vericiguat is being considered for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy / Vericiguat was studied in a population with a high risk of cardiovascular death or heart failure hospitalization / European Commission decision is expected in the coming months (Source: Bayer Company News)
Source: Bayer Company News - May 21, 2021 Category: Pharmaceuticals Source Type: news

IV therapy provider Wellness Flow scouting Columbus for expansion
A year-old provider of intravenous therapy in Dayton is looking at Columbus for expansion. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 15, 2021 Category: American Health Authors: Caleb Stephens Source Type: news

FDA Approves First Drug For Treatment Of Thyroid Eye Disease
The drug is administered via intravenous therapy (IV), with eight infusions over a six month period. Each infusion can take between an hour to an hour and a half. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 25, 2020 Category: Pharmaceuticals Authors: Dana Dovey, Contributor Source Type: news

Gene Therapy May Be Long-Term Cure for Type of Hemophilia
THURSDAY, Jan. 2, 2020 -- A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate. Patients who received the one-time intravenous therapy continue to have a more than... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 2, 2020 Category: General Medicine Source Type: news

Two IV therapy businesses coming to Milwaukee's 3rd Ward
Two businesses that provide intravenous hydration services are adding locations to the 3rd Ward neighborhood in Milwaukee. One business, H2O Health Hydration Oasis, opened its first location in Brookfield. Dr. Alia Fox founded the health and wellness clinic, which offers custom IV therapy. H2O promotes its services as “IV therapy cocktails.” The company markets its “cocktails” as a solution for viral illness es, fatigue, wound healing and hangovers, among other uses. Fox said although IV… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 19, 2019 Category: Pharmaceuticals Authors: Sari Lesk Source Type: news

Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT
RCT (n=1054) found oral antibiotic therapy non-inferior to IV therapy when used during first 6 weeks in treatment for bone/joint infection, as assessed by definitive treatment failure within 1 year of randomisation (14.62% IV vs 13.16% oral), challenging current standard of care (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 27, 2019 Category: Consumer Health News Source Type: news

NIHR Signal: Iron deficiency in people with chronic kidney disease can be managed with either oral or IV therapy
Expert commentary is provided for a review of 39 RCTs (n=3,852) which found that death and cardiovascular death rates were not different for IV and oral iron. Questions remain about cost-effectiveness and tolerability of both oral and IV therapies. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 6, 2019 Category: Consumer Health News Source Type: news

'Stem cell' therapies offered at private clinics need to be approved as drugs, Health Canada says
Across Canada, private clinics charge thousands of dollars for injections and IV therapies using what they claim are stem cells. This week, Health Canada ruled that those cell therapies are drugs that must be approved. But so far, the agency has not ordered clinics to stop doing the procedures. (Source: CBC | Health)
Source: CBC | Health - May 18, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Switching to oral antibiotics early for bone and joint infections gave similar results to continuing intravenous therapy
This research provides good evidence that bone and joint infections can be treated with predominantly oral regimens. This could have several benefits, not least the greater freedom afforded to patients and reduced costs.The importance of taking the medication and potential treatment side effects need to be explained so that patients can seek medical support to modify the treatment when necessary. Also, staff perceptions surrounding the effectiveness of oral antibiotics for this indication also need to be addressed to enable a shift in practice. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news